Pomalidomide CAS: 19171-19-8
MF: C13H11N3O4
MW: 273.24
An inhibitor of LPS-induced TNFαrelease.

Pomalidomide (CAS 19171-19-8)

Pomalidomide | CAS 19171-19-8 is rated 5.0 out of 5 by 1.
  • y_2020, m_3, d_29, h_20
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.5
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364593, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 154ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Synonym: 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline
Application: An inhibitor of LPS-induced TNFαrelease
CAS Number: 19171-19-8
Purity: ≥99%
Molecular Weight: 273.24
Molecular Formula: C13H11N3O4
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

Pomalidomide is thalidomide derivative that displays inhibition of LPS-induced TNFα release. It shows immunomodulator and anticancer effects.

Physical State :
Solid
Solubility :
Soluble in DMSO (55 mg/ml at 25° C), water (<1 mg/ml at 25° C), ethanol (<1 mg/ml at 25° C), 1% DMSO/30% polyethylene glycol/1% Tween 80 (15 mg/ml at 25° C), and THF (sparingly).
Storage :
Store at -20° C
Melting Point :
315.5-317.5° C
Boiling Point :
~582.9° C at 760 mmHg (Predicted)
Density :
~1.6 g/cm3 (Predicted)
Refractive Index :
n20D 1.69 (Predicted)
IC50 :
PBMC: IC50 = 13 nM (human); Lipopolysaccharide stimulated TNF-α release: IC50 = 25 nM (human); Antiproliferative activity against human NAMALWA cells: IC50 = 30 nM; ADMET: IC50 = 0.23 µM; IL-1-α-induced NF-κB activation: IC50 = 1.27 µM (HeLa cells)
pK Values :
pKa: 10.75 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
RTECS :
NR3397905
PubChem CID :
134780
Merck Index :
14: 135
MDL Number :
MFCD12756407
SMILES :
C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 129ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Li et al Li et al. (PubMed ID 23940785) found that Pomalidomide stimulated changes in CNS lymphoma tumor-associated macrophages that led to a reduction in tumor growth rate and prolongation of survival. -SCBT Publication Review
Date published: 2015-05-17
  • y_2020, m_3, d_29, h_20
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.5
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364593, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 21ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.